Although anti‐CD19 CAR‐T cells is an ideal therapeutic method for ALL, often administered for patients with B‐ALL; this approach presents a limited efficacy in patients with T‐cell ALL (T‐ALL). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.